MNKD
HEALTHCAREMannkind Corp
$3.56+0.70 (+24.48%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MNKD Today?
No stock-specific AI insight has been generated for MNKD yet. However, MNKD was mentioned in the following AI insights:
52-Week Range
$2.23$6.51
$3.56
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin0.0%
Debt / Equity—
Trading
Volume36.8M
Avg Volume (10D)—
Shares Outstanding309.0M
MNKD News
20 articles- MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's ChangedYahoo Finance·May 8, 2026
- MannKind Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- MannKind Corporation Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 6, 2026
- MannKind (MNKD) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- MannKind (MNKD) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- MannKind Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Undervalued Small Caps With Insider Buying To Consider In May 2026Yahoo Finance·May 6, 2026
- MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung DiseasesYahoo Finance·May 6, 2026
- Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?Yahoo Finance·May 3, 2026
- MannKind to Report First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 29, 2026
- Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 29, 2026
- How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist UncertaintyYahoo Finance·Apr 22, 2026
- Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside PotentialYahoo Finance·Apr 20, 2026
- B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14Yahoo Finance·Apr 20, 2026
- Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise DevelopmentYahoo Finance·Apr 14, 2026
- Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy?Yahoo Finance·Mar 27, 2026
- How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix PotentialYahoo Finance·Mar 23, 2026
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026Yahoo Finance·Mar 9, 2026
- How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 CatalystsYahoo Finance·Mar 8, 2026
All 20 articles loaded
Price Data
Open$3.44
Previous Close$2.86
Day High$4.29
Day Low$3.40
52 Week High$6.51
52 Week Low$2.23
52-Week Range
$2.23$6.51
$3.56
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin0.0%
Debt / Equity—
Trading
Volume36.8M
Avg Volume (10D)—
Shares Outstanding309.0M
About Mannkind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—